PMID- 27619981
OWN - NLM
STAT- MEDLINE
DCOM- 20180102
LR  - 20181113
IS  - 1573-7373 (Electronic)
IS  - 0167-594X (Print)
IS  - 0167-594X (Linking)
VI  - 130
IP  - 3
DP  - 2016 Dec
TI  - Comparative studies of TIMP-1 immunohistochemistry, TIMP-1 FISH analysis and 
      plasma TIMP-1 in glioblastoma patients.
PG  - 439-448
AB  - Tissue inhibitor of metalloproteinases-1 (TIMP-1) has been associated with poor 
      prognosis and resistance towards chemotherapy in several cancer forms. In a 
      previous study we found an association between a low TIMP-1 tumor 
      immunoreactivity and increased survival for glioblastoma patients, when compared 
      to moderate and high TIMP-1 tumor immunoreactivity. The aim of the present study 
      was to further evaluate TIMP-1 as a biomarker in gliomas by studying TIMP-1 gene 
      copy numbers by fluorescence in situ hybridization (FISH) on 33 glioblastoma 
      biopsies and by measuring levels of TIMP-1 in plasma obtained pre-operatively 
      from 43 patients (31 gliomas including 21 glioblastomas) by enzyme-linked 
      immunosorbent assay (ELISA). The results showed TIMP-1 gene copy numbers per cell 
      ranging from 1 to 5 and the TIMP-1/CEN-X ratio ranging between 0.7 and 1.09, 
      suggesting neither amplification nor loss of the TIMP-1 gene. The TIMP-1 protein 
      levels measured in plasma were not significantly higher than TIMP-1 levels 
      measured in healthy subjects. No correlation was identified between TIMP-1 tumor 
      cell immunoreactivities and the TIMP-1 gene copy numbers or the plasma TIMP-1 
      levels. In conclusion, high immunohistochemical TIMP-1 protein levels in 
      glioblastomas were not caused by TIMP-1 gene amplification and TIMP-1 in plasma 
      was low and not directly related to tumor TIMP-1 immunoreactivity. The study 
      suggests that TIMP-1 immunohistochemistry is the method of choice for future 
      clinical studies evaluating TIMP-1 as a biomarker in glioblastomas.
FAU - Aaberg-Jessen, Charlotte
AU  - Aaberg-Jessen C
AD  - Department of Pathology, Odense University Hospital, Winslowparken 15, 3. Floor, 
      5000, Odense, Denmark.
AD  - Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark.
FAU - Halle, Bo
AU  - Halle B
AD  - Department of Pathology, Odense University Hospital, Winslowparken 15, 3. Floor, 
      5000, Odense, Denmark.
AD  - Department of Neurosurgery, Odense University Hospital, Odense, Denmark.
FAU - Jensen, Stine S
AU  - Jensen SS
AD  - Department of Pathology, Odense University Hospital, Winslowparken 15, 3. Floor, 
      5000, Odense, Denmark.
FAU - Muller, Sven
AU  - Muller S
AD  - DAKO, Glostrup, Denmark.
FAU - Romer, Unni Maria
AU  - Romer UM
AD  - Section of Molecular Disease Biology, Department of Veterinary Disease Biology, 
      Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, 
      Denmark.
FAU - Pedersen, Christian B
AU  - Pedersen CB
AD  - Department of Neurosurgery, Odense University Hospital, Odense, Denmark.
FAU - Brunner, Nils
AU  - Brunner N
AD  - Section of Molecular Disease Biology, Department of Veterinary Disease Biology, 
      Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, 
      Denmark.
FAU - Kristensen, Bjarne W
AU  - Kristensen BW
AD  - Department of Pathology, Odense University Hospital, Winslowparken 15, 3. Floor, 
      5000, Odense, Denmark. bjarne.winther.kristensen@rsyd.dk.
AD  - Institute of Clinical Research, University of Southern Denmark, Odense, Denmark. 
      bjarne.winther.kristensen@rsyd.dk.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160912
PL  - United States
TA  - J Neurooncol
JT  - Journal of neuro-oncology
JID - 8309335
RN  - 0 (Tissue Inhibitor of Metalloproteinase-1)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Brain Neoplasms/*blood/*genetics
MH  - Cohort Studies
MH  - DNA Copy Number Variations
MH  - Denmark
MH  - Female
MH  - Glioblastoma/*blood/*genetics
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Tissue Array Analysis
MH  - Tissue Inhibitor of Metalloproteinase-1/*blood/*genetics
PMC - PMC5118392
OTO - NOTNLM
OT  - Fluorescence in situ hybridization
OT  - Glioblastoma
OT  - Glioma
OT  - Immunohistochemistry
OT  - Plasma
OT  - TIMP-1
COIS- The authors declare no conflict of interest.
EDAT- 2016/09/14 06:00
MHDA- 2018/01/03 06:00
PMCR- 2016/09/12
CRDT- 2016/09/14 06:00
PHST- 2016/01/19 00:00 [received]
PHST- 2016/08/21 00:00 [accepted]
PHST- 2016/09/14 06:00 [pubmed]
PHST- 2018/01/03 06:00 [medline]
PHST- 2016/09/14 06:00 [entrez]
PHST- 2016/09/12 00:00 [pmc-release]
AID - 10.1007/s11060-016-2252-4 [pii]
AID - 2252 [pii]
AID - 10.1007/s11060-016-2252-4 [doi]
PST - ppublish
SO  - J Neurooncol. 2016 Dec;130(3):439-448. doi: 10.1007/s11060-016-2252-4. Epub 2016 
      Sep 12.